Literature DB >> 18316545

Temsirolimus, an inhibitor of mammalian target of rapamycin.

Brian I Rini1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316545     DOI: 10.1158/1078-0432.CCR-07-4719

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  48 in total

Review 1.  Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2011-02       Impact factor: 3.272

2.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

Review 3.  Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.

Authors:  Suman Malempati; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

Review 4.  Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.

Authors:  Joydeep Ghosh; Reuben Kapur
Journal:  Exp Hematol       Date:  2017-03-22       Impact factor: 3.084

Review 5.  Rapamycin passes the torch: a new generation of mTOR inhibitors.

Authors:  Don Benjamin; Marco Colombi; Christoph Moroni; Michael N Hall
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

Review 6.  Updates of mTOR inhibitors.

Authors:  Hongyu Zhou; Yan Luo; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2010-09       Impact factor: 2.505

7.  Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case study.

Authors:  Tatsuya Takayama; Hiroshi Furuse; Fumitake Kai; Takayuki Sugiyama; Seiichiro Ozono
Journal:  Med Oncol       Date:  2013-04-03       Impact factor: 3.064

Review 8.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 9.  Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.

Authors:  Yongchao Zhao; Yi Sun
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

Review 10.  An overview of rapamycin: from discovery to future perspectives.

Authors:  Young Ji Yoo; Hanseong Kim; Sung Ryeol Park; Yeo Joon Yoon
Journal:  J Ind Microbiol Biotechnol       Date:  2016-09-09       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.